In a recent post on the IVI-sponsored Health Affairs featured blog series, Jonathan Silver suggests the key to lowering brand drug prices may be found through patent buyouts and changes to licensing policy. In particular, Silver proposes that non-profit entities be created and funded to purchase and license intellectual property rights for certain branded drugs.
Read the full article here.
About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.
